Avatrombopag for the Treatment of Immune Thrombocytopenia
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14395 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Caterina Labanca und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thiophenes, Thiazoles, Hydrazines. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Avatrombopag, a second‐generation thrombopoietin receptor agonist (TPO‐RA), represents a significant advancement in the treatment of chronic immune thrombocytopenic purpura (cITP) and a potential therapeutic option for other thrombocytopenic disorders. Approved in both the USA and Europe, avatrombopag offers a convenient oral dosing regimen, initiated at 20 mg daily with food, to achieve and maintain platelet counts ≥ 50 × 10 9 /L. Its favorable safety profile, characterized by minimal hepatic toxicity and the absence of dietary restrictions, distinguishes it from older TPO‐RAs such as eltrombopag and romiplostim. Clinical trials and real‐world data support its efficacy, with over 90% of patients that fail to standard first‐ and second‐line treatments or become unresponsive, achieving target platelet counts, and its hepatotoxicity‐free profile makes it particularly advantageous for patients with liver disease or complex comorbidities. Economic evaluations, including a budget impact analysis for the Italian National Health Service, have projected significant healthcare cost savings associated with avatrombopag use, reinforcing its value as a cost‐effective therapeutic option. However, challenges remain, including limited data on long‐term safety. In this review, we aim to provide a comprehensive synthesis of clinical evidence and real‐world data on avatrombopag's efficacy, safety, and pharmacological advantages, while exploring its current and potential therapeutic applications, such as chemotherapy‐induced thrombocytopenia and aplastic anemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
- Laboratorio di Ricerca Traslazionale Azienda USL-IRCSS Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy.
- Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Emilia‑Romagna, Italy.
- Gruppo Amici Dell'Ematologia Foundation-GrADE, Reggio Emilia, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Antonella Bruzzese, Fortunato Morabito
Zitieren
APA
Labanca, C., Vigna, E., Martino, E. A., Bruzzese, A., Mendicino, F., Caridà, G., Lucia, E., Olivito, V., Puccio, N., Neri, A., Morabito, F., & Gentile, M. (2025). Avatrombopag for the Treatment of Immune Thrombocytopenia. European Journal of Haematology. https://doi.org/10.1111/ejh.14395
Vancouver
Labanca C, Vigna E, Martino EA, Bruzzese A, Mendicino F, Caridà G, et al. Avatrombopag for the Treatment of Immune Thrombocytopenia. European Journal of Haematology. 2025. doi:10.1111/ejh.14395
BibTeX
@article{Labanca2025,
author = {Labanca, Caterina and Vigna, Ernesto and Martino, Enrica Antonia and Bruzzese, Antonella and Mendicino, Francesco and Caridà, Giulio and Lucia, Eugenio and Olivito, Virginia and Puccio, Noemi and Neri, Antonino and Morabito, Fortunato and Gentile, Massimo},
title = {Avatrombopag for the Treatment of Immune Thrombocytopenia},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14395}
}
EUVIMED